Form 4: RAPT Director Giordano Receives Annual RSU Grant

RAPT Therapeutics Director Michael F. Giordano was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Michael F. Giordano, a Director of RAPT Therapeutics, Inc. (RAPT), acquired 4,956 shares of common stock.
• The acquisition occurred on January 30, 2026, at a price of $0 per share.
• This transaction represents an annual grant of restricted stock units (RSUs) under the Issuer's Amended & Restated Non-Employee Director Compensation Policy.
• Each RSU signifies a contingent right to receive one share of common stock upon vesting.
• The granted RSUs are scheduled to fully vest on the first anniversary of the grant date, which is January 30, 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, slightly positive event, as it aligns the director's interests with long-term shareholder value through equity compensation, without indicating any significant new operational or financial developments.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for non-employee directors, reflecting a commitment to attracting and retaining qualified board members.

Negatives

• The grant of RSUs, upon vesting, will result in a minor dilution of existing shareholder equity as new shares are issued.

Risks

• The value of the granted restricted stock units is subject to the future market price fluctuations of RAPT Therapeutics' common stock.
• RSUs may be forfeited if the director's service terminates before the vesting date, impacting the director's expected compensation.
• The issuance of shares upon vesting could lead to a slight increase in the total outstanding shares, potentially diluting earnings per share.

Future Outlook

The filing indicates a future vesting event for the granted restricted stock units on January 30, 2027, which will result in the issuance of common stock to the director.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, to non-employee directors are a common and widely accepted practice across the biotechnology and pharmaceutical industries. This method of compensation is designed to align the interests of the board with those of the shareholders, fostering a long-term perspective on company performance and value creation.

Comparison to Industry Standards

• Equity compensation for non-employee directors, often in the form of restricted stock units, is a standard practice across publicly traded companies, including those in the biotech sector. This aligns with compensation structures seen at comparable companies, though specific grant sizes can vary based on company size, performance, and board responsibilities. No specific comparable companies or projects are detailed in this filing.

Related Party Transactions

• The grant of restricted stock units to Director Michael F. Giordano constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors, executed under the established Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, potentially fostering more strategic decision-making. However, it also entails minor future dilution upon vesting.
• Employees: No direct impact on employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated by this specific filing.
• Suppliers: No direct impact on suppliers is indicated by this specific filing.
• Creditors: No direct impact on creditors is indicated by this specific filing.

Next Steps

• The 4,956 restricted stock units are expected to fully vest on January 30, 2027, at which point they will convert into shares of RAPT Therapeutics common stock.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice. While it aligns director interests with shareholders, it does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

RAPT Therapeutics, RAPT, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Michael F. Giordano